Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis

Ann Oncol. 2011 Sep;22(9):2152-2154. doi: 10.1093/annonc/mdr343.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacokinetics*
  • Carcinoma, Renal Cell / metabolism
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / surgery
  • Carcinoma, Renal Cell / therapy*
  • Drug Monitoring
  • Humans
  • Indoles / administration & dosage
  • Indoles / pharmacokinetics*
  • Kidney Neoplasms / metabolism
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / surgery
  • Kidney Neoplasms / therapy*
  • Male
  • Mediastinal Neoplasms / drug therapy*
  • Mediastinal Neoplasms / metabolism
  • Mediastinal Neoplasms / secondary
  • Middle Aged
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / secondary
  • Pyrroles / administration & dosage
  • Pyrroles / pharmacokinetics*
  • Renal Dialysis*
  • Sunitinib

Substances

  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib